Timothy Hansen, MD
MOHS-Micrographic Surgery · Ames, IANPI 1518109123
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 43.1% of the total. Reporting peaked in 2023 at $86 and has fallen 78.2% since, to $19 in 2025.
Across 5 payments — averaging $32.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$71
- Galderma Laboratories, L.p.$45
- Janssen Scientific Affairs, LLC$33
- Pfizer$15
Across 2 payments — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$10K
What the payments were for
- Food & beverage$14991%
- Education$159%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 1 | $71 |
| Galderma Laboratories, L.p. | 2 | $45 |
| Janssen Scientific Affairs, LLC | 1 | $33 |
| Pfizer | 1 | $15 |
How this compares
Too few mohs-micrographic surgery providers in Iowato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 13 | $183,102 |
| Fluorouracil | 31 | $2,346 |
| Clobetasol Propionate | 19 | $889 |
| Tacrolimus | 11 | $755 |
| Ketoconazole | 18 | $537 |
| Dapsone | 11 | $531 |
| Gabapentin | 26 | $391 |
| Halobetasol Propionate | 12 | $368 |
| Triamcinolone Acetonide | 40 | $305 |
| Doxycycline Hyclate | 14 | $241 |
| Cephalexin | 58 | $189 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Ames
- Nicole NegbeneborIowa City$17K
- Andrew BeanWest Des Moines$6K
- Pooja ChitgopekerIowa City$3K
- Spencer McClureIowa City$3K
- Hillary Johnson-JahangirCoralville$895
- Caroline MorrisCedar Rapids$315
- Elizabeth CusickIowa City$185
- Marta Hemmingson-VanbeekIowa City$62
- Hobart WallingCoralville$25
- Kirk SideyIowa City$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.